Contrary to cancer cells (Fig. 3B and Fig. S1D), inhibition of NRG1 binding to HER3 by lumretuzumab, neither decrease proliferation of CAFs nor phosphorylation of AKT and ERK (Fig. 6D and E). This evidence concerns the gene ERBB3 and cancer.